Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Clinical trial NCT01527487 · COMPLETED
Trial details
- NCT number
- NCT01527487
- Sponsor
- SCRI Development Innovations, LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-01
- Primary completion
- 2014-09-01
- Enrollment
- 76
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.